Roche's Susvimo Wins CHMP Backing for First Continuous-Delivery nAMD Treatment in EU
SHERIDAN, WYOMING -- July 30, 2026 -- Roche Holding AG said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of Susvimo for neovascular age-related macular degeneration, positioning the therapy as the first continuous-delivery alternative to standard eye injections in the European Union. The recommendation covers Susvimo as delivered through Roche's Contivue refillable implant, which the company says can maintain vision with as few as two treatments per year. A final decision from the European Commission is expected in the near term. For ophthalmology practices managing high injection volumes, the recommendation signals a potential shift in how a leading cause of vision loss in patients over 60 is treated across the region.